Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Symbiotic-Lung-14: En studie for å lære om studiemedisinen PF08634404 i kombinasjon med cellegift hos voksne deltakere med transformert småcellet lungekreft

6. oktober 2026 oppdatert av: Pfizer

EN FAZE 2 INTERVENSJONSSTUDIE AV PF-08634404 I KOMBINASJON MED KEMOTERAPI HOS DELTAKERE MED TIDLIGERE UBEHANDLET TRANSFORMERT SMÅCELLE LUNGEKREFT

This study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well PF-08634404 works when given alone or with chemotherapy . Chemotherapy is a type of cancer treatment that uses medicines to destroy cancer cells or stop them from growing. The study is for adults with Transformed Small Cell Lung Cancer (T-SCLC ). T SCLC is a rare lung cancer that happens when one type of lung cancer changes into a more aggressive type after treatment stops working.

To join the study, participants must meet the following conditions:

  • Are aged 18 years or older
  • Diagnosed with T-SCLC and have not received treatment for this type of lung cancer (a single cycle of chemotherapy may be permitted)
  • Prior diagnosis of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer treated with tyrosine kinase inhibitors (TKIs)
  • Have healthy organs based on medical tests and are in good physical condition

After joining the study, adults will be given chemotherapy in addition to the study medicine. After this combination treatment is finished, the study medicine will be continued alone. Adults will receive the treatment through IV infusions (medicine given directly into a vein). All treatments will be done at clinical study sites, where a trained medical team will monitor adults during and after each visit.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

40

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • New South Wales
      • Westmead, New South Wales, Australia, 2145
        • Har ikke rekruttert ennå
        • Westmead Hospital
    • South Australia
      • Elizabeth Vale, South Australia, Australia, 5112
        • Rekruttering
        • Calvary Connery Centre
    • Victoria
      • Heidelberg, Victoria, Australia, 3084
        • Har ikke rekruttert ennå
        • Warringal Private Hospital
      • Porto Alegre, Brasil, 90610-000
        • Rekruttering
        • Hospital São Lucas da PUCRS
      • São Paulo, Brasil, 01452-000
        • Har ikke rekruttert ennå
        • Centro Paulista de Oncologia Clínica
    • São Paulo
      • São Paulo, São Paulo, Brasil, 01321-001
        • Rekruttering
        • Hospital Beneficência Portuguesa de São Paulo
    • California
      • Duarte, California, Forente stater, 91010
        • Rekruttering
        • City of Hope National Medical Center
      • Encinitas, California, Forente stater, 92024
        • Rekruttering
        • UC San Diego Medical Center - Encinitas
      • Irvine, California, Forente stater, 92618
        • Rekruttering
        • City of Hope Lennar Foundation Cancer Center
      • La Jolla, California, Forente stater, 92037
        • Rekruttering
        • UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion)
      • La Jolla, California, Forente stater, 92037
        • Rekruttering
        • UC San Diego Sulpizio Cardiovascular Center
      • La Jolla, California, Forente stater, 92037
        • Rekruttering
        • UC San Diego Moores Cancer Center
      • La Jolla, California, Forente stater, 92037
        • Rekruttering
        • UC San Diego Koman Family Outpatient Pavilion
      • San Diego, California, Forente stater, 92101
        • Rekruttering
        • UC San Diego Medical Center - Bankers Hill
      • San Diego, California, Forente stater, 92103
        • Rekruttering
        • UC San Diego McGrath Outpatient Pavilion - Hillcrest
      • San Diego, California, Forente stater, 92127
        • Rekruttering
        • UC San Diego Medical Center - Rancho Bernardo
      • San Diego, California, Forente stater, 92103
        • Rekruttering
        • UC San Diego Medical Center- Hillcrest
      • Vista, California, Forente stater, 92081
        • Rekruttering
        • UC San Diego Medical Center - Vista
    • Illinois
      • Hinsdale, Illinois, Forente stater, 60521
        • Rekruttering
        • Hope and Healing Clinical Research
      • New Lenox, Illinois, Forente stater, 60451
        • Rekruttering
        • Hope and Healing Clinical Research
    • New Jersey
      • Basking Ridge, New Jersey, Forente stater, 07920
        • Rekruttering
        • MSK Basking Ridge
      • Middletown, New Jersey, Forente stater, 07748
        • Rekruttering
        • MSK Monmouth
      • Montvale, New Jersey, Forente stater, 07645
        • Rekruttering
        • MSK Bergen.
    • New York
      • Commack, New York, Forente stater, 11725
        • Rekruttering
        • MSK Commack
      • Harrison, New York, Forente stater, 10604
        • Rekruttering
        • MSK Westchester
      • Long Island City, New York, Forente stater, 11101
        • Rekruttering
        • Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy
      • New York, New York, Forente stater, 10065
        • Rekruttering
        • Memorial Sloan Kettering Cancer Center
      • New York, New York, Forente stater, 10021
        • Rekruttering
        • Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).
      • Uniondale, New York, Forente stater, 11553
        • Rekruttering
        • MSK Nassau
      • Lyon, Frankrike, 69373
        • Rekruttering
        • Centre Léon Bérard
      • Marseille, Frankrike, 13915
        • Rekruttering
        • Assistance Publique Hôpitaux de Marseille - Hôpital Nord
      • Villejuif, Frankrike, 94805
        • Har ikke rekruttert ennå
        • Institut Gustave Roussy
      • Hong Kong, Hong Kong
        • Rekruttering
        • Queen Mary Hospital
      • Hong Kong, Hong Kong
        • Rekruttering
        • Prince of Wales Hospital
    • Kerala
      • Kottayam, Kerala, India, 686630
        • Rekruttering
        • Caritas Hospital and Institute of Health Sciences
    • National Capital Territory of Delhi
      • New Delhi, National Capital Territory of Delhi, India, 110085
        • Rekruttering
        • Rajiv Gandhi Cancer Institute And Research Centre
    • HA Merkaz
      • Ramat Gan, HA Merkaz, Israel, 5265601
        • Rekruttering
        • Sheba Medical Center
    • Jerusalem
      • Jerusalem, Jerusalem, Israel, 9103102
        • Rekruttering
        • Shaare Zedek Medical Center
      • Bergamo, Italia, 24125
        • Rekruttering
        • Cliniche Gavazzeni S.p.A. - Humanitas Gavazzeni
    • ROME
      • Roma, ROME, Italia, 00144
        • Har ikke rekruttert ennå
        • IRCCS Istituto Nazionale dei Tumori Regina Elena
    • Turin
      • Orbassano, Turin, Italia, 10043
        • Rekruttering
        • A.O.U. San Luigi Gonzaga
      • Osaka, Japan, 541-8567
        • Rekruttering
        • Osaka International Cancer Institute(OICI)
    • Aichi-ken
      • Nagoya, Aichi-ken, Japan, 464-8681
        • Rekruttering
        • Aichi Cancer Center Hospital
    • Okayama-ken
      • Kita, Okayama-ken, Japan, 700-8558
        • Har ikke rekruttert ennå
        • Okayama University Hospital
    • Osaka
      • Hirakata, Osaka, Japan, 573-1191
        • Rekruttering
        • Kansai Medical University Hospital
    • Tokyo
      • Chūō, Tokyo, Japan, 104-0045
        • Rekruttering
        • National Cancer Center - Tsukiji Campus
      • Kotoku, Tokyo, Japan, 135-8550
        • Rekruttering
        • Japanese Foundation for Cancer Research
    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100730
        • Rekruttering
        • Peking Union Medical College Hospital
    • Fujian
      • Fuzhou, Fujian, Kina, 350014
        • Rekruttering
        • Fujian Cancer Hospital
    • Henan
      • Zhengzhou, Henan, Kina, 450008
        • Rekruttering
        • Henan Cancer Hospital
    • Hubei
      • Wuhan, Hubei, Kina, 430048
        • Rekruttering
        • Union Hospital Tongji Medical College Huazhong University of Science and Technology
    • Jiangxi
      • Nanchang, Jiangxi, Kina, 330200
        • Rekruttering
        • The First Affiliated Hospital of Nanchang University
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina, 200030
        • Rekruttering
        • Shanghai Chest Hospital
    • Zhejiang
      • Hangzhou, Zhejiang, Kina, 310003
        • Rekruttering
        • The first Affiliated Hospital, Zhejiang University School of Medicine
      • Madrid, Spania, 28041
        • Rekruttering
        • Hospital Universitario 12 de Octubre
      • Seville, Spania, 41013
        • Rekruttering
        • Hospital Universitario Virgen Del Rocio
    • Catalunya [cataluña]
      • L'Hospitalet de Llobregat, Catalunya [cataluña], Spania, 08908
        • Rekruttering
        • Institut Català d'Oncologia - L'Hospitalet
      • Tainan, Taiwan, 704302
        • Rekruttering
        • National Cheng Kung University Hospital
      • Taipei, Taiwan, 100
        • Rekruttering
        • National Taiwan University Hospital
      • Taipei, Taiwan, 11217
        • Rekruttering
        • Taipei Veterans General Hospital
      • Taipei, Taiwan, 106
        • Rekruttering
        • National Taiwan University Cancer Center (NTUCC)

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Male or female participants aged ≥18 years at the time of informed consent.
  • Histologically or cytologically confirmed T-SCLC. Participant must have had a prior diagnosis of NSCLC with EGFR mutation which transformed to SCLC following the treatment with TKI(s).
  • Participants have not received systemic therapy for T-SCLC.
  • Have at least one measurable lesion as the target lesion based on RECIST v1.1.
  • Have sufficient tumor tissue from the diagnosis of transformed SCLC available.
  • Eastern Cooperative Oncology Group performance status of 0 or 1.
  • Have a minimum life expectancy of >12 weeks.
  • Clinical laboratory values at screening within acceptable limits, as defined in the protocol, including: 1) Hematology, 2) Liver function and 3) Renal function.

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Active or untreated CNS disease, including brain, brainstem, spinal cord, or meningeal metastases. Participants with definitively treated, clinically stable brain metastases may be eligible per protocol criteria. Participants with untreated asymptomatic brain metastases of longest diameter <1 cm are permitted if all of the following criteria are met: absence of neurological symptoms, no need for corticosteroids, and brain metastasis has no evidence of edema or hemorrhagic features.

  • Leptomeningeal disease

  • Clinically significant risk of hemorrhage or fistula, including tumor necrosis/cavitation, invasion or compression of major blood vessels, airways, or critical organs, or risk of tracheoesophageal or pleuroesophageal fistula

  • History of another malignancy (other than NSCLC) within 3 years prior to first dose, except for malignancies with negligible risk of metastasis or death (eg, adequately treated carcinoma in situ, nonmelanoma skin cancer)

  • Unresolved toxicity from prior anti-tumor therapy that has not recovered to Grade ≤1 per NCI CTCAE v5.0 (except alopecia or irreversible toxicities deemed stable)

  • History of allogeneic organ or hematopoietic stem cell transplantation

  • Active autoimmune disease requiring systemic treatment within the past 2 years (Stable replacement therapy and selected low-risk autoimmune conditions are permitted per protocol)

  • Interstitial lung disease (ILD), pneumonitis, or significant pulmonary disease, including:

    • Prior or current non-infectious pneumonitis requiring systemic therapy
    • DLCO <50% predicted
    • Severe asthma, COPD, pulmonary embolism, or autoimmune lung involvement
  • Uncontrolled or clinically significant cardiovascular, cerebrovascular, metabolic, hepatic, or renal disease within 6 months prior to first dose

  • Baseline QTcF >480 msec

  • Major surgery or severe trauma within 4 weeks prior to first dose, or planned major surgery during the study

  • Clinically significant pleural effusion, pericardial effusion, or ascites requiring repeated drainage

  • History of significant bleeding disorders or recent major bleeding events

  • Clinically significant gastrointestinal conditions, including recent perforation, fistula, obstruction, or active bleeding

  • Active, uncontrolled, or symptomatic infection, including:

    • Active TB
    • Active hepatitis B or C
    • Uncontrolled HIV infection
  • History of immunodeficiency

  • Severe hypersensitivity or allergic reactions to study intervention components or monoclonal antibodies

  • Psychiatric illness or medical condition, including recent suicidal ideation or behavior, that may increase risk or interfere with study participation

  • Prior anti-angiogenic therapy or other prohibited anti-tumor or immunomodulatory therapies per protocol-specified washout periods

  • Use of prohibited concomitant medications, including high-dose systemic corticosteroids, certain anticoagulants, or live vaccines within protocol-specified timeframes

  • Recent participation in another investigational study (within 30 days or 5 half-lives, whichever is longer)

  • Pregnant or breastfeeding participants, or unwillingness to comply with contraception requirements

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: PF-08634404

Participants will receive PF-08634404 in combination with chemotherapy intravenously, followed by maintenance therapy with PF-08634404.

Injection for intravenous use

Concentrate for solution for infusion

Andre navn:
  • SSGJ-707

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Confirmed Objective Response Rate (ORR) as assessed by investigator based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
Tidsramme: From start of treatment until first documented CR or PR (approximately maximum up to 1 years)

Defined as the proportion of participants in whom a confirmed complete response (CR) or partial response (PR) is observed as best overall response. ORR using RECIST v1.1 as assessed by investigator.

From start of treatment until first documented CR or PR (approximately maximum up to 1 years)
Number of Participants with Adverse Events (AEs)
Tidsramme: Up to 90 days after the last dose of treatment

Adverse Events (AEs) as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention.

Up to 90 days after the last dose of treatment

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Forekomst av antistoff mot PF-08634404
Tidsramme: Opptil 37 dager etter siste dose av behandlingen
Opptil 37 dager etter siste dose av behandlingen
Farmakokinetikk: PF-08634404-serumkonsentrasjoner før og etter dosering
Tidsramme: Opptil 37 dager etter siste dose behandling
Opptil 37 dager etter siste dose behandling
Progression Free Survival (PFS) as assessed by investigator based on RECIST v1.1
Tidsramme: Up to approximately 2 years after completion of study treatment of last study participant

PFS is defined as the time from the date of randomization to the date of first documented disease progression, per RECIST v1.1, or death to any cause, whichever occurs first

Up to approximately 2 years after completion of study treatment of last study participant
Number of participants with Laboratory abnormalities
Tidsramme: Up to 90 days after the last dose of treatment

Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing.

Up to 90 days after the last dose of treatment
Duration of Response (DOR) as assessed by investigator based on RECIST v1.1
Tidsramme: Up to approximately 2 years after completion of study treatment of last study participant

DOR is defined as the time from the first documentation of objective response (CR or PR) to the date of first documentation of disease progression (PD) or death due to any cause.

Up to approximately 2 years after completion of study treatment of last study participant
Overall Survival (OS)
Tidsramme: Up to approximately 2 years after completion of study treatment of last study participant

OS is defined as the time from the date of randomization to the date of death due to any cause. OS is secondary outcome measure in Phase 2 portion of the study.

Up to approximately 2 years after completion of study treatment of last study participant

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: Pfizer CT.gov Call Center, Pfizer

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

2. juli 2026

Primær fullføring (Antatt)

24. mars 2028

Studiet fullført (Antatt)

24. mars 2031

Datoer for studieregistrering

Først innsendt

13. mars 2026

Først innsendt som oppfylte QC-kriteriene

13. mars 2026

Først lagt ut (Faktiske)

17. mars 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

9. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

6. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere